graves'%20disease
GRAVES' DISEASE
Graves' disease is an autoimmune disorder that results into overproduction of thyroid hormones.
Thyrotoxicosis signs and symptoms include hyperactivity, irritability, insomnia, dysphoria, sweating, heat intolerance, palpitations, weakness, fatigue, weight loss despite increased appetite, diarrhea, steatorrhea polyuria, decreased libido, tachycardia, tremor, goiter, alopecia, gynecomastia, eyelid lag or retraction and rarely periodic paralysis.
Clinical features in thyrotoxic patient that suggests Graves's disease are ophthalmopathy, thyroid dermopathy, thyroid acropachy, diffuse goiter, antibodies to thyroid peroxidase or thyroglobulin and thyroid radionuclide scan demonstrating a diffuse goiter.

Radiotherapy

Radioactive Iodine Therapy

  • Usually 1st-line agent for patients ≥50 yr, & in North America
    • Antithyroid agents are usually 1st-line treatment elsewhere
  • Preferred treatment for females planning pregnancy in the future, individuals w/ comorbidities increasing surgical risk & patients w/ previously operated or externally irradiated necks
  • Can be used as initial treatment or for relapses after trial of antithyroid agents
  • Effects: 80-95% of patients remain euthyroid after treatment
    • Usually takes 4-8 wk to control symptoms
    • Large goiter requires large dose to reduce risk of recurrence
    • 10-30% of patients become hypothyroid w/in 2 yr after treatment; 5% per yr thereafter
  • Pretreatment w/ other agents
    • Antithyroid agents: Usually unnecessary w/ mild-moderate disease, but necessary for severe disease (discontinue for at least 3 days prior to treatment & can be resumed 2-3 days after treatment)
    • Beta-blocker may also be used prior to treatment to control symptoms
  • Posttreatment
    • Antithyroid agents have radioprotective effect; therefore, administer after treatment only in poorly controlled hyperthyroidism
  • Thyroid replacement should be carefully titrated as patient evolves from euthyroidism to hypothyroidism
  • Contraindicated in pregnant women, breastfeeding
    • Pregnancy should be deferred at least 4-6 mth
    • Pregnancy test should be done w/in 48 hr prior to treatment
  • Can induce or worsen ophthalmopathy, particularly in smokers
  • Consent form should be signed before initiating treatment
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2015
Long-term oral testosterone undecanoate significantly improved IPSS quality of life scores in a 1-year, randomised, multicentre, double-blind trial among aging hypogonadal men.
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

Rachel Soon, 01 Jun 2016

Patients with hypercholesterolaemia with unchanging LDL-cholesterol levels after 6 weeks of statin treatment should be actively assessed for either statin intolerance or resistance, says an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

Prof. Cyrus Rustam Kumana, 07 Jul 2016

This case scenario was presented at a grand round in the Department of Medicine, The University of Hong Kong. Unlike traditional grand rounds that directly or indirectly deal with clinical challenges posed by patients, this one was equally about doctors and how they care for their charges. All doctors who tend patients dread being implicated on the receiving end of medico-legal proceedings. This topic is therefore intimately linked to the professionalism of doctors, their standing in the community, and the ethical aspects of how they interact with patients and relatives.